201 related articles for article (PubMed ID: 24535624)
1. Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.
Grossman SS
Adv Ther; 2014 Mar; 31(3):247-63. PubMed ID: 24535624
[TBL] [Abstract][Full Text] [Related]
2. Once weekly exenatide: efficacy, tolerability and place in therapy.
Wysham C; Grimm M; Chen S
Diabetes Obes Metab; 2013 Oct; 15(10):871-81. PubMed ID: 23425609
[TBL] [Abstract][Full Text] [Related]
3. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
Trautmann ME; Van Gaal L; Han J; Hardy E
J Diabetes Complications; 2017 Sep; 31(9):1415-1422. PubMed ID: 28669463
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.
Iwamoto K; Nasu R; Yamamura A; Kothare PA; Mace K; Wolka AM; Linnebjerg H
Endocr J; 2009; 56(8):951-62. PubMed ID: 19706990
[TBL] [Abstract][Full Text] [Related]
8. Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
Brunton S; Davidson JA
Clin Ther; 2016 Mar; 38(3):582-94. PubMed ID: 26926319
[TBL] [Abstract][Full Text] [Related]
9. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
Stonehouse A; Walsh B; Cuddihy R
Diabetes Technol Ther; 2011 Oct; 13(10):1063-9. PubMed ID: 21732798
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
Henry RR; Klein EJ; Han J; Iqbal N
Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
13. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
[TBL] [Abstract][Full Text] [Related]
14. Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
Busch RS; Ruggles J; Han J; Hardy E
Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29044860
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
Wysham CH; MacConell L; Hardy E
Diabetes Care; 2016 Oct; 39(10):1768-76. PubMed ID: 27436275
[TBL] [Abstract][Full Text] [Related]
16. Exenatide once weekly for the treatment of type 2 diabetes.
Malone J; Trautmann M; Wilhelm K; Taylor K; Kendall DM
Expert Opin Investig Drugs; 2009 Mar; 18(3):359-67. PubMed ID: 19243286
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.
Sheu WH; Brunell SC; Blase E
Diabetes Res Clin Pract; 2016 Apr; 114():160-72. PubMed ID: 26827116
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
Trujillo J
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
